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1. Introduction  
Molecular composition of pregnant women blood plasma/serum is an indispensable tool 
for biochemists in the field of routine prenatal diagnostics aimed at the detection of the most 
common aneuploidies.  
Predictive power of some biochemical markers respectively their sum is an important guide 
for the assessment of the status of the fetus and pregnancy.  
But the diagnostic potential of maternal plasma is much broader.  
Fragmented and apoptically degraded fetal cells and nucleic acid molecules, which 
overcame the placental (feto-maternal) barrier and got under the influence of the immune 
system of the mother, offer other options for molecular biologists.  
Some of them will focus on the clarification of rules between the quantity of fetal molecules 
and pathology of the placenta and the fetus others are engaged in direct diagnostic potential.   
In the maternal blood circulation can be detected fetal genetic material of a different 
integrity ranging from the nuclear DNA of living cells through fetal apoptically partially 
degraded molecules more or less packed in nucleoides to completely fragmented DNA 
molecules  mostly of size between 100 - 400 bp. Cell free fetal (cff) mRNA molecules  from 
trophoblast are also presented in detectable concentration in maternal plasma. 
While the presence of fetal cells in maternal circulation is quite rare (1 fetal cell in 1 million 
maternal cells), the quantity of cffDNA molecules in plasma is considerably higher (typically 
3 % - 6 %).   
2. Source and transport of cff nucleic acid molecules into maternal plasma 
The ways in which cffDNA forms and how gets into the maternal circulation, are not yet 
fully clarified. There are several hypotheses on the origin of cff DNA. 
The main source of free DNA appears to be a placenta (Wataganara & Bianchi, 2004). Most 
likely the cff DNA forms by disintegration of placental cells and the direct transition to the 
maternal circulation.  
Another possibility is that the placenta functions as an mediator of transition for DNA 
circulating in the fetal blood circuit into maternal tissues.  
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In this case, there should be a two-way traffic, however, the amount of analyzed fetal DNA 
in maternal plasma is much greater than the amount of free maternal DNA in umbilical 
plasma in childbirth (Sekizawa et al., 2003). It is indicative of an unequal transfer of free 
DNA from fetus to the mother. Another source of fetal molecules may be fetal hematopoietic 
cells which get into the maternal circulation (Bianchi, 2004). The fetal DNA is apoptically 
released into maternal plasma due to the effect of maternal immune system (Pertl et al., 
2000). Apoptotic fetal cells were found in detectable concentrations also directly in the 
plasma (Van Wijk et al., 2000). Apoptosis proven in maternal plasma (Sekizawa et al., 2003) 
or in cord blood (Hristoskova et al., 2001) suggests that this mechanism could be an 
important source of fetal material. Another hypothesis assumes a simple diffusion of shorter 
DNA molecules from the amniotic fluid through placenta or membranes into maternal 
circulation. This DNA then comes from various fetal tissues. 
Cff DNA was also demonstrated in the maternal plasma even before feto-maternal 
circulation establishment. This means that the DNA could be of the trofoblastic origin 
(Bianchi et al., 2004).   In general, it could be assumed that cff DNA in maternal circulation is 
of different origin but its large portion likely comes from the trophoblastic placental tissue. 
The transfer of fetal molecules through the feto-maternal barrier is continuous during 
pregnancy and after the delivery they are quickly eliminated from plasma (16 min halftime 
of degradation (Lo et al., 1999).  
Free fetal RNA allows non-invasive prenatal profiling of gene expression and offers a 
number of research and diagnostic applications on the basis of easily detectable mRNA 
transcripts from placentally expressed genes in maternal plasma (Ng et al., 2003).  
Considering serious degradation as a result of the activities of the ribonucleases, the stability 
of mRNA molecules in fetal free plasma is surprising. Plasma RNA molecules are much 
more stable than isolated and purified RNA molecules. Mechanisms that protect the 
circulating free fetal RNA are not fully clarified at present time. However their conjunction 
with the sub cellular particles could prevent their degradation (Hasselmann et al., 2001).  
They can form complexes with proteins, lipids, lipoproteins, phospholipids bound to the 
DNA in nucleosomes or within protected apoptotic corpuscles or other vesicular structures 
(Halicka et al., 2000; Hasselmann et al., 2001; Tsui et al., 2002; Sisko et al., 2001).   
The stability of placental mRNA molecules in maternal plasma is a promising assumption 
that fetal markers at the level of mRNA will be clinically useful.  
It could be useful for prenatal detection of some pregnancy pathologies, including pre-
eclampsia and certain chromosomal aneuploidies (Ng et al., 2004).    
3. Placental trophoblast and trisomy 21 
Trophoblast with chromosome 21 trisomy  shows disturbed both cell fusion and  formation 
of syncytiotrofoblast (ST) (Frendo et al., 2000b; Massin et al., 2001). An activation of caspases 
is necessary for formation of ST in early stage of differentiation (Huppertz and Kingdom, 
2004). If ST is inadequate, the individual trophoblastic cells with trisomy 21 could continue 
on in the cascade of apoptic events and release more fragmented cff DNA than disomic 
trophoblastic cells. Another possible cause for the release of larger amounts of fetal 
molecules in pregnancy with trisomy 21 is a continuation of trophoblastic cells in the 
improper proliferation, without initiating events leading to the formation of ST. In this case 
maternal immune system would regulate the division by increased degradation of fetal 
cells. 
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4. Fragmentation profile of cffDNA 
Publications, relating to the characterization of the DNA fragments in the plasma, are aimed 
to the level of fragmentation of fetal molecules related to the maternal ones in the course of 
pregnancy. For pregnant women were described in plasma longer fragments in comparison 
with non-pregnant women (Chan et al., 2004).  
Real-time PCR is the most commonly used procedure for the analysis of fetal DNA 
fragments in present time (Alberry et al., 2009; Ariga et al., 2001; Lo et al., 1998). Honda et al. 
(2002) described the sensitivity of the detection of fetal DNA for this method and 
determined it at 5,38 copies/ml of the peripheral blood. 
Molecules of fetal origin are more degraded and shorter than the maternal and their size is 
approximately in the range from 100 bp - to 700 bp. (Zhong et al., 2000; Koide et al., 2005). 
Fragments above 1 kb belong mostly to the mother (Li et al., 2004). 
We have evaluated fragment analysis using three methods (capillary electrophoresis of STR 
loci, capillary electrophoresis and Real-time PCR of gonozomal sequences) from two 
different perspectives. The first relied on direct analysis of the size of fractions and the 
second assessed PCR efficiency with respect to the size of amplified DNA molecules 
(Vodicka et al., 2010).  
Direct detection of fetal molecules has confirmed a large heterogeneity in the individual 
fractions both by capillary electrophoresis and Real-time PCR.   
A direct dependency of fetal molecules on the week of pregnancy has been suggested only 
in the size fraction of 500 - 760 bp. Regression modeling at STR and gonozomal analyses was 
the most accurate in the pD system, where the size of molecules ranged from 395 bp to  
440 bp. Statistical significance of regression declined towards the smaller molecules.  
The fragment size was 200 bp to 223 bp in the D21S1446 system and 157-188 bp in D21S1435.  
Regression analysis was inconclusive in the AMELY (molecule size 109 bp). 
If we compare analysis of the size of fractions to the results of the effectiveness of the STR 
and gonozomal analyses (Vodicka et al., 2008a), where was demonstrated statistically 
significant increase of fetal molecules in all 3 STR systems, we found out that it was 
confirmed an interesting trend, which indicates an increase in the larger fetal molecules 
during pregnancy while the number of smaller molecules of fetal origin does not change.   
In the case of quantification using SRY probe, whose length is 64 bp it was observed even 
reverse trend and the number of amplified molecules in 150-300 bp fraction was in indirect 
relation to the week of gestation.  
The tendency has decreased for larger fractions and in total plasma the trend has stopped 
even slightly reversed.  
On the basis of these observations, we can therefore assume the most sensitive detection of 
fetal material using short probes. But these probes are not much suitable for quantitative 
analysis.  Fractions from 400 bp above are the most appropriate for the assessment of the 
amount of fetal material, although in these fractions the relative amount of fetal DNA is less. 
The importance of this study resides in decision-making, whether, from a diagnostic point 
of view, it is more important a detection of fetal molecules or their quantification (Vodicka 
et al., 2010). 
5. The extraction of cffDNA/RNA from maternal peripheral blood 
5.1 CffDNA isolation procedures 
An essential precondition for the success of all subsequent procedures is a sufficient yield, 
reproducibility and the purity of the isolated plasma cffDNA.  Isolation procedures are most 
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often based on double centrifugation and subsequent binding (adsorption) of DNA 
molecules on a silica surface of membrane or magnetic particles.  
5.1.1 Isolation by binding to a silica-gel membrane 
The adsorption on silica surface is one of the most common techniques which is able to 
capture free fragmented DNA.  
Silicate polymer in the presence of chaotropic salts (e.g. sodium iodide or guanidine 
thiocyanate) specifically binds to the DNA molecule on the surface of silicon dioxide 
(usually specially prepared glass) and in the presence of water or other elution reagent, 
which has a very low content of salt, this molecule releases from its surface.  
High specificity of the link between DNA molecule and silicate material is useful in 
eliminating other extracellular substances.   
5.1.2 Isolation by binding to the magnetic particles 
Methods based on the (para) magnetic particles (MPs) are other approach to the cffDNA 
isolation. MPs are particles of size from 5 nm to 100 µm, consisting of a metal core, it is 
usually Ǆ-Fe2O3 (maghemit) or Fe3O4 (magnetite) but could be also for example Au.  
The core is coated with a layer that has specifically prepared surface for binding the 
molecules that we want to isolate.  
The size of the MPs can be adapted according to the molecules which we are isolating: 5-50 
nm proteins; 20-450 nm nucleic acids; 10-100 µm viruses.  
MPs respond to the external magnetic field and are capable to bind different bioreaktive 
molecules, because of their affinity to the modified surface, directly from the biological 
material. The isolation is then as follows.  
MPs are added to the sample where bind with the targeted molecule. Modified MPs are then 
attracted by magnet to the wall of the tube and the remaining solution with non-bind 
substances is removed.  
The MPs with joined molecules are subsequently washed and released in added solution.  
Bound molecules are separated from the MPs by some physical-chemical step (denaturing 
or change in pH).  
This way we obtain targeted molecules which could be afterward analyzed (Húska et al., 
2008).    
5.1.3 Comparison of silica-gel to magentic particles methods 
Both above mentioned isolation procedures were tested in our workplace.   
For a comparison, cff DNA (male fetus)  was measured and quantified both by Real-time 
PCR in SRY locus and by quantitative fluorescent (QF) PCR and capillary electrophoresis 
separation  in AMELY locus in  38 samples from the 1st and 38 samples from the 2nd 
trimester. While the concentrations of total DNA measured spectrophotometrically were 
similar there were substantial differences in yield of cffDNA between tested DNA extraction 
methods (graph 1,2).  
Isolation based on the separation of magnetic particles had significantly lower recovery 
compared with the amount of cffDNA extracted by binding on the silicate membrane. 
According to our current findings "silica membrane" based method seemed to be clearly 
more suitable for isolation of cffDNA from the plasma of pregnant women.  
DNA extraction using magnetic particles should present a simple way how relatively easily 
and without contamination obtained the cffDNA.  
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Graph 1. Comparison of silica gel and magnetic particles isolation effectiveness by Real-time 
PCR quantification. 
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Graph 2. Comparison of silica gel and magnetic particles isolation effectiveness by capillary 
electrophoresis quantification  
However, for the isolation of short fragments of cffDNA this method did not work, although 
the manufacturer declares, that it should be able to detect the DNA molecules of the size 
from 50 bp to 1,5 kb. Low efficiency of cffDNA capture can be caused by strong bond of free 
fragmented fetal DNA on magnetic particles, or by contraries, by weaker bond of these 
fragments on magnetic particles and their wash out during isolation.  
To explain this, we re-isolated unbound DNA from supernatant. The subsequent 
quantification by capillary electrophoresis has demonstrated again only the maternal 
sequences, which suggests a stronger link of fragmented fetal DNA on magnetic particles.   
If cffDNA was succsessfully  detected by both methods, the amount of DNA has correlated 
to each other (Graph 3). 
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Graph 3. Correlation of the results of free fetal DNA quantification by capillary 
electrophoresis and real-time PCR (RT-PCR). The Y axis shows the Relative fluorescence 
units (RFU) obtained from capillary electrophoresis, X axis shows the fluorescence scanned 
in Real time system. 
5.2 Cff mRNA isolation procedures 
To maintain integrity of obtained free fetal RNA, it is important to use isolation techniques 
which have minimum isolation steps, are quick and contain RNA stabilizers.  
Currently there are no commercially produced kits standardized for isolation of free fetal 
RNA directly from maternal plasma, but there are available kits specialized for isolation of 
viral RNA, which could be, with little modification, applied to the isolation of free fetal 
RNA.  
Double centrifugation in cooled centrifuge or ultra centrifugation is necessary for separation 
of cellular component of blood prior to the isolation of free fetal RNA. 
The combination of viral RNA Kit and vacuum pumps seems to be an optimal system for 
obtaining free fetal RNA in the highest possible quantity and the quality, with minimal risk 
of contamination during isolation, unlike centrifugation steps. Microfilters can be used to 
increase the concentration of free fetal RNA. 
6. The use of cff DNA for diagnostic purposes 
The resolution of the fetal genotype and precise quantification of cffDNA are crucial for 
diagnostic purposes.  
6.1 Noninvasive fetal sex determination by cffDNA 
So far, the most common and relatively simple for the analysis of fetal DNA was the use of Y 
specific sequences from male fetuses.  
These sequences can be quantified by methods of Real-time PCR and QF PCR. 
The methodology for fetal sex detection in maternal plasma is already relatively well 
developed and reliable (Lo et al., 1998; Honda et al., 2002; Wei et al., 2001; Zhong et al., 2000, 
Vodicka et al., 2008b).   
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Our quick and simplify fetal sex detection is based on refined QF PCR. We tested 475 DNA 
samples isolated from maternal plasma in different weeks of pregnancy ranging from 4th 
w.g. to 37th w.g. Y chromosomal sequences in AMELY were tested and quantify by 
comparison to AMELX using capillary electrophoresis.  
The method is able to distinguish even less than 1 % of Y chromosomal sequences of 
artificial mixtures. Fetal sex was detected with 4.05 % of false positivity and 7.15 % of false 
negativity (Vodicka et al., 2008).   
The methodology has very high detection sensitivity, which is comparable with a sensitivity 
of real-time PCR methodology (Sekizawa et al., 2001; Honda et al., 2002).  
Possible contamination of the samples during collection and in the course of the isolation 
procedure is the main cause of false-positive detection of the male sex. 
Minimization of any contamination is fundamental in sensitive DNA analyses in which it is 
necessary to capture the genotype in quantities of about 5%.   
Mistakes in determination of male fetus (false-negative results) come mostly from early 
stages of pregnancy, when the concentration of cffDNA is still very low, so rather than non-
compliance could be assessed these results as missing fetal DNA. 
Capillary electrophoresis has proven to be uniquely able to capture even 1 % genotype 
artificial admixture.  
The result of examinations of our group of pregnant women can be considered very 
satisfactory. The methodology is prepared for practical use, however, further improvement 
of isolation robustness and following laboratory procedures may increase specificity, 
sensitivity, and the yield of fetal DNA. 
6.2 Noninvasive RHD genotyping by cffDNA 
RHD genotype of the fetus can be identified from maternal plasma already at the beginning 
of pregnancy using molecular analysis of cffDNA.  
Clinical significance of determination of fetal RhD status is dual:  
1. Noninvasive fetal RHD determination from peripheral blood of Rh- alloimmunized 
pregnant women at the beginning of pregnancy allows to determine the fetuses which 
are really threatened by development of hemolytic disease of fetus and newborn. 
2. If anti-D antibodies are not present at the beginning of pregnancy, RhD negative 
woman should be provided with anti-D immunoglobulin during pregnancy in 
sufficient dosage for each potentially sensitizing events including completion of 
antepartal prophylaxis at 28th week of gestation. Potentially sensitizing event means 
any situation in which may occur intersection of RhD positive fetal erythrocytes to the 
mother's blood, and subsequent development of the RhD alloimmunization (chorionic 
villus sampling, amniocentesis, cordocentesis, another intervention of the prenatal 
diagnosis and fetal therapy, obstetric hemorrhage in the 2nd and 3rd trimester, 
intrauterine death of fetus). Prevention of RhD alloimmunization should be provided to 
RhD negative pregnant woman by delivery of anti-D immunoglobulin in sufficient 
dosage in all above-mentioned cases. The administration of anti-d immunoglobulin is 
necessary if the fetus is RhD-positive, on the contrary, if the fetus is RhD negative, the 
pregnant woman is not threatened by the development of the RhD alloimmunization 
and administration of anti-D immunoglobulin is not necessary.  
RHD genotyping of cffDNA is most often done using Taq man Real time PCR with probes 
from exone 7, 10, 4 or 5. System of negative and positive PCR control in addition to internal 
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control of PCR amplification is necessary for the reliability of detection considering great 
sensitivity of the method. At the same time, you must have created calibration quantitative 
profile for exact specification of detection limit of RhD positivity.  
6.3 Noninvasive cffDNA analysis of monogenic inherited diseases 
CffDNA can be also used for examination of monogenic inherited diseases.   
Many genetic abnormalities, for example autosomal dominant myotonic dystrophy 
(Amicucci et al., 2000), Huntington's disease (Gonzalez-Gonzalez et al., 2003) or gene 
mutations such as achondroplasia (Saito et al., 2000) has already been examined from 
cffDNA. Furthermore, it is possible to detect some autosomal recessive diseases, such as 
cystic fibrosis (Gonzalez-Gonzalez et al., 2002) or ǃ-talasemia (Chiu et al., 2002). 
7. Cff nucleic acid quantitation for noninvasive Down syndrome diagnostics 
Targeted molecular analysis of fetal aneuploidy with maternal plasma utilization is more 
complicated and applicable differentiation of maternal and fetal genotypes within the 
desired chromosome brings with it many challenges.  
Considering differences between the quantity of total cffDNA and cfDNA, in the fetuses 
with Down syndrome (DS) pathology can be observed a greater quantity of cffDNA 
compared to the physiological pregnancies (Vodicka et al, 2008a).  
The total amount of cffDNA cannot be considered as unambiguous marker due to large 
variation in the amount of cffDNA in physiological pregnancies and, rather, it is possible to 
include it to the system of ultrasound and biochemical markers.  
Direct examination of the loci responsible for the DS brings a substantial improvement of 
the diagnosis. Currently, there are several approaches or their combinations respectively, 
aimed to unambiguous resolution of pathological fetus with the DS. 
7.1 Noninvasive cffDNA diagnostics of Down syndrome using genotype differences 
between paternal and maternal genotypes 
DS analyses and quantifications of cffDNA are based on the resolution of paternal from 
maternal genotypes. The fetus must be always heterozygous for the monitored loci. 
Previous genotyping of the parents is therefore important for the selection of appropriate 
markers. 
Targeted resolution assumes a sufficient number of reliable analyzable markers of paternal 
(fetal) origin on chromosome 21 and at the same time a sufficient number of reliable markers 
outside the chromosome 21.   
The genotype of the fetus can be distinguished by means of DNA sequence variation using 
male specific sequences for male fetus, short tandem repeats (STR) or single nucleotide 
polymorphisms (SNP).   
For the estimation of the relative amounts of cffDNA originating in chromosome 21 it is 
necessary to choose a strategy that combines the creation of sensitive and accurate 
calibration standards for each marker and reciprocal measuring of cffDNA amount from the 
locus on chromosome 21 and cffDNA quantity from autosomal locus or locus on 
chromosome Y respectively.    
If the measurement is accurate enough, then the amount of cffDNA of chromosome 21 
related to the quantity of the cffDNA locus outside the chromosome 21 should differ in the 
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case of trisomy 21 from disomy 21. It is clearly distinguishable in the case of trisomy of 
paternal origin, where the extra chromosome comes from the father.   
The methodology of quantitative calculations for STR loci on chromosome 21, where was 
mainly taken into account the relative length of alleles and preferential amplification of the 
shorter alleles has been developed at our department.  
In pregnancies with trisomy 21, it was found statistically more cffDNA for systems in which 
the length of PCR products ranged mostly between 200 bp - 400 bp (Vodicka et al., 2008).  
In total six genes that are specifically expressed in trofoblastic tissues (placenta) has been 
selected for quantification and genotyping on the DNA level in loci responsible for Down 
syndrome and for reference SNP genotyping (Böhmova et al. 2010). 
These genes are DSCR4, KRTAP26-1, PLAC4, PLAC1, PAPPA and PSG11 of them DSCR4, 
KRTAP26-1 and PLAC4 are localized on chromosome 21 in the area responsible for Down 
syndrome. In total 12 SNPs were selected for genotyping in these genes.  
Balanced allelic frequency for particular SNP alleles reported in the database of the NCBI 
website was the criterion for the SNP selection. For individual SNP variants have been 
defined TaqMan probes. Individual genotypes were identified initially by sequencing of the 
SNP regions for 30 randomly selected maternal DNA samples. Subsequently TaqMan Real 
Time PCR optimization and calibration was carried out.  
Quantifiler kit (Applied Biosystems) has been used for verification of the quality of the 
dilutive series of calibration standards. The quantification itself was carried out on 240 DNA 
samples isolated from plasma of pregnant women in the 1st and 2nd   trimester.  
Heterozygozity in particular SNP ranged from 14 % to 55 % and the probability of 
appropriate genotypes capture for each SNP was stated in the range from 12 % to 28 %. 
Sensitivity of minor genotype capture depends on fluorescence background of non-
specifically hybridized probe.  
Taqman SNP probes were able to capture as low as 1 percent of artificial genotypic mixture 
and by the most sensitive systems we have detected 0,22 % artificial genotypic mixture.  
R2 values were in the range of 0,995 to 0,999 and the inclination (angular coefficient) 
assessing the effectiveness of the PCR (tendency around the values of -3.3 shows the 
optimum, 100% PCR amplification) from -3.2 to -3.6. All standard calibration curves were 
appropriate for the cffDNA quantification (Picture 1). 
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Picture 1. Quantity assessment of cffDNA using calibration curve in SNP1 of PAPPA 
Cff DNA was analyzed only for the detectable genotypes. The detection ability ranged from 
11.8 % to 100 %. The amount of cffDNA was very variable (from about 0.02 ng to 13 ng 
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cffDNA in 200 ul of the plasma).  All 12 selected SNP are able to detect cffDNA with the 
desired probability. Parameters of the calibration curve are suitable for the precise 
quantification of cffDNA (Picture 1) (Böhmova et al., 2010).    
7.2 Noninvasive cff mRNA analysis for Down syndrome diagnostics 
Placental tissue is ontogenetically much unrelated to blood cells and may express other 
genes whose expression is missing in maternal blood cells. The first work, which confirmed 
the RNA of fetal origin, was published in 2000 (Poon et al., 2000). 
Using microarray technology in the maternal plasma have been detected RNA markers 
whose expression is specific to the placenta (Tsui et al., 2004). The same approach was used 
in the study, which described the cff mRNA transcribed from gene PLAC4 (placenta-specific 
4), which is located on chromosome 21.  
On the basis of the assumption of uniform batch theory (3 alleles of PLAC4 gene, without 
allele-specific preferential transcription, express 1/3 more mRNA than 2 alleles) quantitative 
detection of disomic and trizomic dose was developed. With the use of the SNP in the 
heterozygous state in the gene coding for the PLAC4  there were detected disomic fetus 
ratio 1: 1 and trizomic ratio  2: 1 with 90% of the diagnostic sensitivity and 96.5% specificity 
of trisomy 21 capture by mass spectrometry technique (Lo et al., 2007a). 
The disadvantage of this method is relatively labour-intensive preparation of high-quality 
and reproducible matrix for mass spectrophotometry RNA analysis. Another limiting factor 
is the real amount of cff mRNA molecules in the isolate from plasma, which could affect the 
evenness of distribution of mRNA molecules transcribed from individual alleles. Only 
sufficient number of SNPs can assure desired heterozygozity. Therefore it is necessary to 
test and introduce new mRNA SNP markers (Go et al., 2007; Yang et al., 2008). 
Another approach of measuring allelic SNP ratios in cff mRNA has been tested using digital 
PCR. It is based on the assumption that, in the PCR reaction is either 1 or no molecule of 
cDNA. PCR is carried out in parallel in many hundreds to thousands of mixtures. According 
to the number of positive responses, you can estimate an initial number of cff RNA 
molecules with a particular SNP and by measuring of the ratios between the SNP from RNA 
derived from chromosome 21 and another autosome, you can detect chromosome 21 
trisomy with high sensitivity (Lo et al., 2007b). 
7.3 Noninvasive Down syndrome diagnostics by cffDNA epigenetic detection and 
quantification 
Methodology relies on different methylation of maternal and fetal or placental sequence. 
Sequences, which are subject to methylation are on principle situated in CpG islands of 
promoter areas. These islets may regulate the transcription of the gene by variable degree of 
methylation. In different tissues there are promoters of genes whose expression is tissue 
specific, and which are methylated differently, and specifically for the type of tissue.  
Different fetal (placental) and maternal methylation of regions on chromosome 21 were 
tracked for the purposes of Down Syndrome non-invasive prenatal diagnostics.  Different 
methylation showed 22 out of 114 assessed genomic regions on this chromosome (Chim et 
al., 2008).  
This relatively large number of methylation specific fetal DNA sequences offers a promising 
source of prenatal biomarkers independent on maternal and fetal genotype.  
Large loss of genetic material (90 %) in the course of DNA modification, based on cytosine 
deamination using bisulphite, is a disadvantage of this epigenetic way of examination. 
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The modification procedure, somewhat laborious, in addition increases the risk of 
contamination.  Additional distortion of results could be due to heterogeneous methylation 
of CpG islands.  
Some laboratories are trying to test methods that would eliminate the a forementioned 
shortcomings (Chan et al., 2006; Tong et al., 2007). 
Digital methyl sensitive PCR, methyl sensitive HRM and, probably, massive parallel DNA 
sequencing are the most promising prospective technologies for precise quantification of 
epialleles. 
7.4 Combination of genetic/epigenetic/cff mRNA methods  
To increase the diagnostic sensitivity it is possible to combine methodological approaches, 
based on cffDNA, cff mRNA and hyper/hypomethylated placental DNA.  
Tong et al (2010) published the epigenetic quantification of hypermethylated placental DNA 
from chromosome 21 (locus HLCS) using digital PCR and compared it to the male specific 
genetic marker of the Y chromosome.    
The relative quantities of the epigenetic marker were shown to be increased for fetus with 
trisomy 21 compared to disomic fetus. This approach is very sensitive even for the DS 
diagnosis in the first trimester.  
It will be appropriate to use different paternal genetic polymorphic markers at the level of 
the SNP or STR instead of male specific genetic marker.  
To increase the reliability of resolution of trisomy 21 from disomy 21 is also possible to 
perform relative quantification of cffDNA/cff mRNA using exonal SNP of chromosome 21 
and exonal SNP from the reference autosome. 
8. Tasks for future 
For the successful development of high accurate detection of DS and other frequent 
trisomies it is necessary to attend to the following tasks:  
- Choice of isolation procedures for plasmatic DNA fragments length of which 
corresponds to the fetal molecules. 
- Protection of plasmatic molecules from the disintegration of maternal lymphocytes.  
- Prevention of free plasmatic fetal RNA degradation. 
- Loss minimization during modification of hyper/hypomethylated DNA. 
- Provision of sufficient number of reliable genetic and epigenetic fetal markers.  
- More sensitive optimization of calibration and quantification for HRM, Real time PCR 
and QF PCR. 
- Introduction of automation of digital PCR and digital HRM for quantification of 
CffDNA/cff mRNA/modified cffDNA. 
9. Conclusion 
Almost 15 years have passed since the first work, which pointed to the presence of the cff 
DNA in maternal plasma of pregnant women (Lo et al., 1997). 
Since then many authors gradually contributed more and more theoretical and 
methodological knowledge. 
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Nowadays, also thanks to introduction of new and more robust technologies we can boldly 
predict that direct clinical outcome of this multi-year effort of noninvasive prenatal 
diagnostics  of Down Syndrome will be feasible in very near future. 
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